Pienta KJ - Search Results

1

A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.

Rosenthal SA, Hunt D, Sartor AO, Pienta KJ, Gomella L, Grignon D, Rajan R, Kerlin KJ, Jones CU, Dobelbower M, Shipley WU, Zeitzer K, Hamstra DA, Donavanik V, Rotman M, Hartford AC, Michalski J, Seider M, Kim H, Kuban DA, Moughan J, Sandler H. Rosenthal SA, et al. Among authors: pienta kj. Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):294-302. doi: 10.1016/j.ijrobp.2015.05.024. Epub 2015 Jul 21. Int J Radiat Oncol Biol Phys. 2015. PMID: 26209502 Free PMC article. Clinical Trial.

2

A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate.

Pienta KJ, Redman BG, Esper PS, Flaherty LE. Pienta KJ, et al. Am J Clin Oncol. 1996 Oct;19(5):500-3. doi: 10.1097/00000421-199610000-00014. Am J Clin Oncol. 1996. PMID: 8823479 Clinical Trial.

3

Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate.

Pienta KJ, Esper PS, Zwas F, Krzeminski R, Flaherty LE. Pienta KJ, et al. Am J Clin Oncol. 1997 Feb;20(1):36-9. doi: 10.1097/00000421-199702000-00008. Am J Clin Oncol. 1997. PMID: 9020285 Clinical Trial.

4

The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer.

Smith DC, Pienta KJ. Smith DC, et al. Among authors: pienta kj. Urol Clin North Am. 1997 May;24(2):433-7. doi: 10.1016/s0094-0143(05)70390-6. Urol Clin North Am. 1997. PMID: 9126241

5

A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.

Pienta KJ, Redman BG, Bandekar R, Strawderman M, Cease K, Esper PS, Naik H, Smith DC. Pienta KJ, et al. Urology. 1997 Sep;50(3):401-6; discussion 406-7. doi: 10.1016/S0090-4295(97)00228-8. Urology. 1997. PMID: 9301705 Clinical Trial.

6

Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.

Pienta KJ, Smith DC. Pienta KJ, et al. Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-72-S15-77. Semin Oncol. 1997. PMID: 9346227 Clinical Trial.

7

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. Smith DC, et al. Among authors: pienta kj. Urology. 1998 Aug;52(2):257-60. doi: 10.1016/s0090-4295(98)00173-3. Urology. 1998. PMID: 9697791 Clinical Trial.

8

Quality-of-life evaluation in patients receiving treatment for advanced prostate cancer.

Esper P, Hampton JN, Smith DC, Pienta KJ. Esper P, et al. Among authors: pienta kj. Oncol Nurs Forum. 1999 Jan-Feb;26(1):107-12. Oncol Nurs Forum. 1999. PMID: 9921573

9

Paclitaxel in the treatment of hormone-refractory prostate cancer.

Smith DC, Pienta KJ. Smith DC, et al. Among authors: pienta kj. Semin Oncol. 1999 Feb;26(1 Suppl 2):109-11. Semin Oncol. 1999. PMID: 10190791 Review.

10

Oral chemotherapy for hormone refractory prostate cancer. The University of Michigan experience.

Kamradt JM, Smith DC, Pienta KJ. Kamradt JM, et al. Among authors: pienta kj. Urol Clin North Am. 1999 May;26(2):333-40. doi: 10.1016/s0094-0143(05)70073-2. Urol Clin North Am. 1999. PMID: 10361556

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

651 results

Search Page

Filters